ANV600 - Anaveon
Keytruda (pembrolizumab) - Merck (MSD)
https://oncologypro.esmo.org/congress-resources/esmo-immuno-oncology-congress-2025?presentation=expand_1__a_phase_i_ii_study_of_anv600__a_pd_1_tar_84038df
 
M. Imbimbo1; E. Calvo2; I. Korakis3; P. Tomasini4; S. Cousin5; T.O. Goetze6; K. Ouali7; A. Desuki8; V. Gambardella9; G. Alonso Casal10; N. Steeghs11; S. Ochsenreither12; Y. Shao13; A.M. Tsimberidou14; R. Galot15; A. Vilalta16; M.J. Chisamore17; K. Richter18; R. Sachse19; M. Joerger20
 
Oct 27, 2025
 
Prev Next